TORONTO, March 20,
2025 /PRNewswire/ - Auxly Cannabis Group Inc.
(TSX: XLY) (OTCQB: CBWTF) ("Auxly" or the
"Company") a leading consumer packaged goods company in
the cannabis products market, today released its financial results
for the fourth quarter and full year ended December 31, 2024. These filings and additional
information regarding Auxly are available for review on SEDAR
at www.sedar.com. All amounts are Canadian dollars
except common shares
("Shares") and per Share amounts.
Highlights for the fourth quarter ended December 31, 2024 and subsequent events:
- Net revenue of $34.6 million, an
increase of 29% over the prior year period.
- Gross Margin on Finished Cannabis Inventory Sold1,
of 54% in 2024, up from 40% in 2023.
- SG&A of $9.3 million, a
reduction of 5% over the prior year period.
- Adjusted EBITDA1 of $11.0
million or 32% of net revenue, up from $2.3 million in 2023.
- Cash flow from operations of $3.2
million and cash at quarter end totalled $18.4 million.
- 4th largest Canadian Licensed Producer, with market
share of 6.0% at quarter end2.
- Back Forty exited the quarter as the #1 cannabis brand in
Canada and remains the #1 brand
today2.
Highlights for the year ended December
31, 2024:
- Net revenue of $122.3 million, an
increase of 21% over the prior year.
- Gross Margin on Finished Cannabis Inventory Sold1 of
46% in 2024, up from 34% in 2023.
- SG&A of $35.7 million, a
reduction of 8% compared to 2023.
- Adjusted EBITDA1 of $26.7
million or 22% of net revenue, up from $1.5 million in 2023.
- Total Debt1 reduced by 56% in 2024 with the
conversion of over $123 million of
debt into shares by Imperial Brands plc and repayment of the
outstanding standby debenture facility.
- The Company's Back Forty all-in-one vape was recognized by
budtenders as the "Innovation of the Year" at the 2024 KIND
awards.
- The Company held the #1 position nationally in the non-infused
pre-roll category.
_______________________________
|
1 Non-IFRS
or supplementary financial measure. Refer to the Non-GAAP Measures
section in the MD&A for definitions.
|
2 All retail
data is sourced from Hifyre IQ, as of December 2024 and March
2025.
|
Management Commentary
"The Auxly team delivered an outstanding year, driven by our
unwavering commitment to innovation, gross margin expansion, and
operational excellence," said Hugo
Alves, Founder and Chief Executive Officer of Auxly. "With
demand for THC in Canada and
around the world at an all-time high, Auxly is uniquely positioned
to capitalize on this opportunity through our large-scale, low-cost
cultivation advantage and innovation leadership in the largest,
fastest-growing product categories. We are just getting started and
excited about the road ahead and will remain focused on driving
sustainable, profitable growth and creating meaningful value for
all of our stakeholders."
Auxly President Mike Lickver
echoed this optimism, stating, "Our success is a testament to the
dedication of our team, the loyalty of our consumers, and the trust
of our partners. We made tremendous strides in brand awareness,
culminating in Back Forty emerging as the #1 cannabis brand in
Canada by the end of 2024. As we
move forward, our commitment to superior product quality and
consumer-centric brands will continue to strengthen Auxly's
leadership in the Canadian cannabis market."
Year End Highlights and Key Performance Indicators
For the three months
ended:
|
December
31,
|
December 31,
|
|
|
(000's)
|
2024
|
2023
|
Change
|
% Change
|
Net revenues
|
$
34,626
|
$
26,909
|
$
7,717
|
29 %
|
Gross margin on
finished cannabis inventory sold*
|
18,684
|
10,804
|
7,880
|
73 %
|
Gross margin on
finished cannabis inventory sold (%)*
|
54 %
|
40 %
|
14 %
|
35 %
|
Net
income/(loss)
|
4,423
|
(54,020)
|
58,443
|
108 %
|
Adjusted
EBITDA*
|
11,006
|
2,294
|
8,712
|
380 %
|
Weighted average shares
outstanding - basic
|
1,284,329,265
|
1,005,194,829
|
279,134,436
|
28 %
|
|
|
|
|
|
For the years
ended:
|
December
31,
|
December 31,
|
|
|
(000's)
|
2024
|
2023
|
Change
|
% Change
|
Net revenues
|
$
122,329
|
$
101,078
|
$
21,251
|
21 %
|
Gross margin on
finished cannabis inventory sold*
|
55,861
|
34,295
|
21,566
|
63 %
|
Gross margin on
finished cannabis inventory sold (%)*
|
46 %
|
34 %
|
12 %
|
35 %
|
Net
income/(loss)
|
(16,348)
|
(44,511)
|
28,163
|
63 %
|
Adjusted
EBITDA*
|
26,705
|
1,471
|
25,234
|
1715 %
|
Weighted average shares
outstanding - basic
|
1,204,591,972
|
990,994,056
|
213,597,916
|
22 %
|
|
|
|
|
|
As at:
|
December
31,
|
December 31,
|
|
|
(000's)
|
2024
|
2022
|
Change
|
% Change
|
Cash and
equivalents
|
$
18,356
|
$
15,608
|
$
2,748
|
18 %
|
Total assets
|
261,530
|
261,904
|
(374)
|
0 %
|
Debt*
|
54,683
|
123,579
|
(68,896)
|
-56 %
|
|
|
|
|
|
*Non-IFRS or
supplementary financial measure. Refer to the Non-GAAP Measures
section for definitions.
|
Results of Operations
(000's)
For the years
ended:
|
December 31, 2024
|
December 31, 2023
|
Revenues
|
|
|
Revenue from
sales of cannabis products
|
$
185,666
|
$ 151,762
|
Excise taxes
|
(63,337)
|
(50,684)
|
Total Net Revenues
|
122,329
|
101,078
|
Cost of
Sales
Costs of finished cannabis inventory sold
|
66,468
|
66,783
|
Inventory
impairment
|
2,332
|
10,474
|
Gross profit/(loss) excluding fair value items
|
53,529
|
23,821
|
Unrealized fair
value gain / (loss) on biological transformation
|
32,627
|
16,207
|
Realized fair
value gain/(loss) on inventory
|
(26,227)
|
(18,751)
|
Gross profit
|
59,929
|
21,277
|
Expenses
|
|
|
Selling, general, and administrative expenses
|
35,676
|
38,641
|
Equity-based
compensation
|
5,055
|
1,641
|
Depreciation and amortization
|
4,484
|
6,943
|
Interest and
accretion expense
|
15,041
|
25,715
|
Total expenses
|
60,256
|
72,940
|
Other incomes
/ (losses)
|
|
|
Interest and
other income
|
240
|
32
|
Impairment of assets
|
-
|
(39,706)
|
Gain/(loss) on settlement of assets and liabilities and other expenses
Gain/(loss) on
disposal of assets held for sale
Gain/(loss) on
disposal of subsidiary
|
1,401
(453)
-
|
48,365
-
(4,006)
|
Foreign exchange gain/(loss)
|
(1,217)
|
(771)
|
Total other income/(loss)
|
(29)
|
3,914
|
Net income/(loss) before income tax
|
(356)
|
(47,749)
|
Income tax
recovery/(expense)
|
(15,992)
|
3,238
|
Net
income/(loss)
|
$(16,348)
|
$(44,511)
|
Adjusted EBITDA
|
$
26,705
|
$
1,471
|
Net income/(loss)
per common share (basic and diluted)
|
$
(0.01)
|
$
(0.04)
|
Weighted average
shares outstanding (basic and diluted)
|
1,204,591,972
|
990,994,056
|
Net Revenues
For the year ended December 31,
2024, net revenues were $122.3
million as compared to $101.1
million during the same period in 2023, representing
increases of 21%. Revenues for the year ended December 31, 2024 were comprised of approximately
61% (2023 – 61%) in sales of dried flower and pre-roll Cannabis
Products, with the remainder from oils and Cannabis 2.0 Product
sales.
For the year ended December 31,
2024, approximately 76% (2023 – 82%) of cannabis sales
originated from sales to British
Columbia, Alberta and
Ontario. During 2024, the Company
had sales in all Canadian provinces and the Yukon and Northwest
Territories.
Gross Profit
Auxly realized a gross profit of $59.9
million for the year ended December
31, 2024, resulting in a 49% Gross Profit Margin,
respectively as compared to $21.3
million or 21% during the same periods in 2023. The Gross
Margin on Finished Cannabis Inventory Sold for the year ended
December 31, 2024 improved to 46%
versus 34% in 2023 as a result of the streamlining and improvements
made in the Company's manufacturing process to reduce operating
costs and increased demand and pricing of adult-use recreational
market and bulk flower products.
Realized and unrealized fair value gains and losses reflect
accounting treatments associated with Auxly Leamington cultivation
activities and sales and are influenced by changes in production,
sales and net realizable value assumptions.
Inventory impairments during 2024 of $2.3
million were associated with charges related to reductions
in net realizable value of dried cannabis under the Company's
product specifications and obsolescence of certain retired products
and packaging, a decrease of $8.1
million from the comparative period.
Total Expenses
Selling, general and administrative expenses ("SG&A") are
comprised of wages and benefits, office and administrative,
professional fees, business development, and selling expenses.
SG&A expenses were $35.7 million
in 2024, $3.0 million or 8% lower
than 2023. The decrease in SG&A was primarily as a result of
measures taken to reduce overhead in the organization.
Wages and benefits were $16.9
million for the year, as compared to $16.3 million during 2023. Wages and benefits in
2023 included a positive adjustment to compensation accruals.
Excluding the adjustments to compensation accruals in 2023, wages
and benefits decreased compared to 2023 due to the streamlining of
operations and support staff as a result of a more focused product
portfolio.
Office and administrative expenses were $5.2 million for the year, $5.2 million lower than the same period in 2023.
The decreased expenditures were primarily related to streamlining
of operations, lower corporate head office spending, and reduced
insurance expenses.
Auxly's professional fees were $2.2
million during 2024, $0.8
million lower than 2023. Professional fees incurred
primarily related to accounting fees, regulatory matters, reporting
issuer fees, and legal fees associated with certain corporate
activities and as a result can fluctuate significantly from one
period to the next.
Business development expenses were $0.4
million for year ended December 31,
2024 as compared to $0.5
million for the same period in 2023. These expenses
primarily relate to business development and travel related
expenses.
Selling expenses were $11.0
million for the year ended December
31, 2024, an increase of $2.5
million from the same periods in 2023. The increase in
expenditures was primarily as a result of investments in marketing
initiatives and higher Health Canada fees related to higher
revenues.
Equity-based compensation for the year was $5.1 million, primarily due to the impact of the
increased closing price of the Company's Shares as at December 31, 2024 on the value of Cash Settled
RSUs granted in 2023 and RSUs issued in 2024. During the same
period in 2023, equity-based compensation was $1.6 million.
Depreciation and amortization expenses were $4.5 million for 2024, representing a decrease of
$2.5 million over 2023. The decreases
were primarily as a result of reductions in intangible assets and
depreciation associated with disposed assets, including the
transition out of the Auxly Ottawa Carleton Place facility.
Interest expenses were $15.0 million for the year ended
December 31, 2024, a decrease of
$10.7 million over the same period in
2023. The decrease in expenses were primarily a result of the
conversion of Imperial Debentures into Shares and lower interest
expense on adjustable-rate debt, partially offset by interest from
newly financed obligations. Interest expense includes accretion on
the convertible debentures and interest paid in kind on the
Imperial Debenture. Interest payable in cash was approximately
$8.8 million for 2024, $0.5 million lower than 2023 as a result of lower
principal amounts outstanding on debt instruments.
Total Other Incomes and Losses
Total other incomes and losses was $nil for 2024, compared to
net gains of $3.9 million in 2023.
The other incomes and losses in 2024 included gains on settlement
of assets and liabilities, the extensions of the unsecured
promissory notes and gains on the sale of equipment, offset by
foreign exchange losses, the loss on the adjustment to the
provision related to the claim filed by Kindred Partners Inc. and
the loss on the sale of the Auxly Ottawa facility. The net gains in
2023 were primarily driven by the gains on the extension of the
Imperial Brands Debenture and the unsecured promissory notes,
partially offset by $35.9 million of
impairment of other assets, noting that the Company's market
capitalization traded significantly below its shareholders' equity.
Other income and losses in 2023 also included the closure of the
Auxly Ottawa facility where the carrying value exceeded the fair
value less cost to sell, and the disposal of Inverell.
Net Income and Loss
Net loss for the year ended December 31,
2024 was $16.3 million,
representing a net loss of $0.01 per
share on a basic and diluted basis. The net loss of $16.3 million for 2024 included $16.0 million of deferred tax expense on the
conversion of Imperial Debenture into Shares. Excluding the gains
on the extension of the Imperial Brands Debenture in the third
quarter of 2023 of $46.9 million and
the after-tax charges of $32.7
million related to the impairment of other assets during the
fourth quarter of 2023, net income increased by $42.4 million primarily due to improved gross
profits and reduction in expenses, including the operational
stability as a result of the consolidation of the Company's dried
flower and pre-roll manufacturing to the Auxly Leamington
facility.
Adjusted EBITDA
Adjusted EBITDA was $26.7 million
for the year, an improvement of $25.2
million when compared to $1.5
million during 2023. Adjusted EBITDA for the year ended
December 31, 2024 improved primarily
as a result of improved gross profits and lower SG&A.
Outlook
As the Company looks ahead to 2025, it remains steadfast in its
commitment to profitable growth. Building on a record-breaking
year, the Company expects to further improve in 2025 through
focused innovation, expansion of our distribution footprint and
enhanced production efficiency.
At the core of the Company's strategy is its commitment to
teamwork and the excellence of its people. The Company will
continue to foster an inclusive, collaborative, high-performance
culture with a shared commitment to quality, innovation and
continuous improvement. The Company's people are the foundation of
its success, and the Company will continue to invest in their
development. By empowering the team with the tools, training, and
leadership needed to excel, the Company will drive operational
discipline, efficiency and success in all areas of the
business.
The Company will continue to build on its track record of
product innovation leadership. The Company's commitment to consumer
insights and its culture of operational agility and speed to market
in a sector where consumer preferences evolve rapidly will continue
to support its excellence in this area. In 2024, the Company
accepted several new genetics into commercial production from its
dried flower research and development program. Two of these
strains, Liquid Imagination and Fire Breath, were top selling
flower products in Canada in 2024.
In the pre-roll category, the Company was the first to introduce
the extra large 0.75g format in the straight-cut pre-roll segment
and developed in-house automation technology for coating infused
pre-rolls, improving product quality and enhancing efficiency. The
Company's Back Forty all-in-one vapes significantly grew the
category and shifted the demand for new vape products, winning
"Innovation of the year" at the KIND Industry Awards. All of these
product innovations highlight Auxly's ability to achieve
market-leading success across its key categories and underpins the
Company's continued financial success in a market where consumer
preferences are dynamic and still evolving. The Company's
innovation leadership in the largest and fastest-growing product
categories is a competitive advantage.
The Company anticipates continued market success across its core
categories through focus and execution. This includes defending the
leadership position of the Back Forty brand, which exited 2024 as
the #1 brand in Canada by retail
sales. The Company will expand its domestic distribution channels
and continue to assess available options for sustainable
international expansion. The Company will continue to deepen its
relationships with retailers across the country to ensure that our
products are always accessible. The Company will remain dedicated
to consumer and competitor insights and will refine its proprietary
business intelligence tools to maximize the value proposition of
its product offerings.
Efficiency remains a key priority as Auxly remains focused on
profitable growth. In 2024, the Company successfully increased
cultivation yields at its Auxly Leamington facility by increasing
plant density and optimizing post-harvest processes. The Company
has identified further areas to expand production in 2025 on a
capital-light basis. The Company will leverage its culture of
continuous improvement by improving its supply chain, enhancing
inventory management, and building in-house capabilities for
international market diversification.
Enhancing financial stability is a key piece of the Company's
corporate strategy. The Company's disciplined approach to capital
management has reduced overhead expenses and strengthened its
balance sheet. In 2024, the Company reduced total debt by 56% and
refinanced its debt facilities. In the coming year, the Company
will maintain a sharp focus on reducing debt and its cost of
capital, while working with its existing capital partners to ensure
long-term stability and liquidity needed for continued profitable
growth.
Looking ahead, the Company is confident in its ability to
continue delivering exceptional results by focusing on innovation,
operational excellence, and profitable growth in its key
categories. By executing on its strategic priorities, the Company
will reinforce its leadership in the Canadian cannabis market,
fortify its foundations for continued profitable growth and create
value for all of its stakeholders in 2025 and beyond.
Non- GAAP Measures
Please see the Company's MD&A dated March 20, 2025, under "Non-GAAP Measures" for a
further description of the following financial and supplementary
financial measures.
Financial Measures
EBITDA and Adjusted EBITDA
These are non-GAAP measures used in the cannabis industry and by
the Company to assess operating performance removing the impacts
and volatility of non-cash and other adjustments. The definition
may differ by issuer. The Adjusted EBITDA reconciliation is as
follows:
(000's)
|
Q1/23
|
Q2/23
|
Q3/23
|
Q4/23
|
Q1/24
|
Q2/24
|
Q3/24
|
Q4/24
|
Net
income/(loss)
|
$
(10,249)
|
$
(12,863)
|
$
32,621
|
$
(54,020)
|
$(26,012)
|
$
2,002
|
$
3,239
|
$
4,423
|
Interest and accretion
expense
|
5,808
|
6,457
|
6,613
|
6,837
|
6,868
|
2,749
|
3,133
|
2,291
|
Interest and other
income
|
(14)
|
20
|
(16)
|
(22)
|
(19)
|
(140)
|
(54)
|
(27)
|
Income tax
expense/(recovery)
|
-
|
-
|
-
|
(3,238)
|
15,992
|
-
|
-
|
-
|
Depreciation and
amortization
included in cost of sales
|
1,120
|
911
|
1,151
|
1,084
|
1,292
|
1,780
|
1,382
|
1,338
|
Depreciation and
amortization
included in expenses
|
1,745
|
1,673
|
1,817
|
1,708
|
1,230
|
1,067
|
1,197
|
990
|
EBITDA
|
(1,590)
|
(3,802)
|
42,186
|
(47,651)
|
(649)
|
7,458
|
8,897
|
9,015
|
|
|
|
|
|
|
|
|
|
Impairment of
inventory
|
673
|
1,459
|
3,233
|
5,109
|
456
|
473
|
674
|
729
|
Unrealized fair value
loss/(gain) on biological transformation
|
(4,247)
|
(4,713)
|
(4,766)
|
(2,481)
|
(2,773)
|
(8,817)
|
(9,964)
|
(11,073)
|
Realized fair value
loss/(gain) on inventory
|
4,639
|
3,146
|
5,538
|
5,428
|
2,435
|
4,464
|
7,703
|
11,625
|
Restructuring and
acquisition costs
|
165
|
86
|
29
|
131
|
-
|
655
|
(75)
|
271
|
Equity-based
compensation
|
409
|
377
|
707
|
148
|
1,927
|
701
|
1,324
|
1,103
|
Impairment of
assets
|
-
|
2,588
|
-
|
37,118
|
-
|
-
|
-
|
-
|
Non-recurring bad debt
expense/(recovery)
|
-
|
780
|
360
|
-
|
-
|
-
|
(123)
|
-
|
(Gain)/loss on
settlement of assets, liabilities and disposals
|
-
|
(1,478)
|
(46,887)
|
4,006
|
634
|
62
|
(183)
|
(1,461)
|
Foreign exchange
loss/(gain)
|
89
|
479
|
(283)
|
486
|
210
|
177
|
33
|
797
|
Adjusted
EBITDA
|
$
138
|
$
(1,078)
|
$
117
|
$ 2,294
|
$
2,240
|
$
5,173
|
$
8,286
|
$
11,006
|
Supplementary Financial Measures
Gross Margin on Finished Cannabis Inventory Sold
"Gross Margin on Finished Cannabis Inventory Sold" is a
supplementary financial measure and is defined as net revenues less
cost of finished cannabis inventory sold divided by net
revenues.
Gross Profit Margin
"Gross Profit Margin" is defined as gross profit divided by net
revenues. Gross Profit Margin is a supplementary financial
measure.
Debt
"Debt" is defined as current and long-term debt and is a
supplementary financial measure. It is a useful measure in managing
the Company's capital structure and financing requirements.
ON BEHALF OF THE BOARD
"Hugo Alves" CEO
About Auxly Cannabis Group Inc. (TSX: XLY)
Auxly is a leading Canadian consumer packaged goods company in
the cannabis products market, headquartered in Toronto, Canada. Our mission is to help
consumers live happier lives through quality cannabis products that
they trust and love.
Our vision is to be a global leader quality cannabis
products.
Learn more at www.auxly.com and stay up to date at Twitter:
@AuxlyGroup; Instagram: @auxlygroup; Facebook:
@auxlygroup; LinkedIn: company/auxlygroup/.
Notice Regarding Forward Looking Information:
This news release contains certain "forward‐looking information"
within the meaning of applicable Canadian securities law. Forward
looking information is frequently characterized by words such as
"plan", "continue", "expect", "project", "intend", "believe",
"anticipate", "estimate", "may", "will", "potential", "proposed"
and other similar words, or information that certain events or
conditions "may" or "will" occur. This information is only a
prediction. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward‐looking information throughout this news release.
Forward‐looking information includes, but is not limited to: the
proposed operation of Auxly, its subsidiaries and partners; the
intention to grow the business, operations and existing and
potential activities of Auxly; proposed timelines for the
build‐out, expansion, licencing or commercialization of the
Company's facilities and projects; the Company's execution of
its innovative product development, commercialization strategy and
expansion plans; the Company's intention to introduce innovative
new cannabis products to the market and the timing thereof; the
anticipated benefits of the Company's partnerships, research and
development initiatives and other commercial arrangements; the
expectation, timing and quantum of future revenues, Gross Margin on
Finished Cannabis Inventory Sold, SG&A and of positive Adjusted
EBITDA; expectations regarding the Company's expansion of sales,
operations and investment into foreign jurisdictions; future
legislative and regulatory developments involving cannabis and
cannabis products; the timing and outcomes of regulatory or
intellectual property decisions; the ability of the Company to
maintain and grow its market share; the relevance of Auxly's
subsidiaries' current and proposed products with provincial
purchasers and consumers; consumer preferences; political change;
competition and other risks affecting the Company in particular and
the cannabis industry generally.
A number of factors could cause actual
results to differ
materially from a conclusion, forecast
or projection contained in the forward‐looking
information in this release including, but not limited to, whether:
the Company will be able to execute on its business strategy
or achieve its goals; Auxly's subsidiaries are able to maintain the
necessary governmental and regulatory authorizations to conduct
business; the Company is able to successfully manage the
integration of its various business units with its own; the
Company's subsidiaries obtain and maintain all necessary
governmental and regulatory permits and approvals for the operation
of their facilities and the development of cannabis products, and
whether such permits and approvals can be obtained in a
timely manner; the Company will be able to successfully launch new
product formats and enter into new markets; there is acceptance and
demand for current and future Company products by consumers
and provincial purchasers; the Company will be able to increase and
maintain revenues, maintain positive Adjusted EBITDA, and/or
achieve and maintain its target Gross Margin on Finished Cannabis
Inventory Sold; risks relating to the overall macroeconomic
environment, which may impact customer spending, the Company's
costs and margins, including tariffs (and related retaliatory
measures), the levels of inflation, and interest rates; and general
economic, financial market, legislative, regulatory, competitive
and
political conditions in which the Company and its subsidiaries and partners operate
will remain the same. Additional risk
factors are disclosed in the annual information form of the Company
for the financial year ended December 31, 2024 dated
March 20, 2025.
New factors emerge from time to time, and it is not possible for
management to predict all of those factors or to assess in advance
the impact of each such factor on the Company's business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward‐looking information. The forward‐looking information in
this release is based on information currently available and what
management believes are reasonable assumptions. Forward‐ looking
information speaks only to such assumptions as of the date of this
release. In addition, this release may contain forward‐looking
information attributed to third party industry sources, the
accuracy of which has not been verified by the Company. The
forward‐looking information is being provided for the purposes of
assisting the reader in understanding the Company's financial
performance, financial position and cash flows as at and for
periods ended on certain dates and to present information about
management's current expectations and plans relating to the future,
and the reader is cautioned that such forward‐ looking information
may not be appropriate for any other purpose. Readers should not
place undue reliance on forward‐looking information contained in
this release.
The forward‐looking information contained in this release is
expressly qualified by the foregoing cautionary statements and is
made as of the date of this release. Except as may be required by
applicable securities laws, the Company does not undertake any
obligation to publicly update or revise any forward‐ looking
information to reflect events or circumstances after the date of
this release or to reflect the occurrence of unanticipated events,
whether as a result of new information, future events or results,
or otherwise.
Neither Toronto Stock Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the Toronto
Stock Exchange) accepts responsibility for the adequacy or accuracy
of this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/auxly-reports-2024-fourth-quarter-and-full-year-results-achieves-record-sales-and-profitability-back-forty-exits-2024-as-the-1-brand-in-canada-302406805.html
SOURCE Auxly Cannabis Group Inc.